Israël - anglais - Ministry of Health

pfizer pharmaceuticals israel ltd - sunitinib as malate - capsules - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israël - anglais - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - * * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israël - anglais - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israël - anglais - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Singapour - anglais - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - pralatrexate - infusion, solution - 20mg/ml - pralatrexate 20mg/ml

Singapour - anglais - HSA (Health Sciences Authority)

roche singapore pte. ltd. - tocilizumab - infusion, solution concentrate - 20mg/ml - tocilizumab 20mg/ml

Singapour - anglais - HSA (Health Sciences Authority)

merck pte. ltd. - cetuximab, chimeric antibody - infusion, solution - 5mg/ml - cetuximab, chimeric antibody 5mg/ml

Singapour - anglais - HSA (Health Sciences Authority)

lotus international pte. ltd. - ixabepilone - injection, powder, lyophilized, for solution - 15 mg/vial - ixabepilone 15 mg/vial

Singapour - anglais - HSA (Health Sciences Authority)

lotus international pte. ltd. - ixabepilone - injection, powder, lyophilized, for solution - 45 mg/vial - ixabepilone 45 mg/vial

Singapour - anglais - HSA (Health Sciences Authority)

roche singapore pte. ltd. - rituximab - infusion, solution concentrate - 10mg/ml - rituximab 10mg/ml